Challenges and progress in the development of a serogroup B meningococcal vaccine.
Serogroup B meningococci cause the majority of the meningococcal disease burden in developed countries. Production of an effective and safe vaccine for serogroup B organisms has been hampered by the poor immunogenicity of the capsular polysaccharide that defines this group of bacteria. Previous effo...
Main Authors: | Lewis, S, Sadarangani, M, Hoe, J, Pollard, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2009
|
Similar Items
-
Serogroup B meningococcal vaccines-an unfinished story.
by: Sadarangani, M, et al.
Published: (2010) -
Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
by: Pollard, A, et al.
Published: (2013) -
Recent progress in the prevention of serogroup B meningococcal disease
by: Feavers, I, et al.
Published: (2017) -
Meningococcal serogroup B vaccines: Estimating breadth of coverage
by: Robert G. K. Donald, et al.
Published: (2017-02-01) -
Will booster doses be required for serogroup B meningococcal vaccine?
by: McQuaid, F, et al.
Published: (2014)